Hyperbaric oxygen therapy versus Risperidone in autistic children: a comparative study

Hyperbaric oxygen therapy versus Risperidone in autistic children: a comparative study - Hyperbaric oxygen therapy versus Risperidone in autism

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041613

Enrollment

180

Registered

2020-09-01

Start date

2019-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism spectrum disorder

Interventions

Group A (60):received forty sessions of Hyperbaric oxygen therapy. Group B (60):received Risperidone for 6 months. Group C (60):No treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children diagnosed ASD by neurologist or psychiatrist based on (DSM-5)

Exclusion criteria

Exclusion criteria: 1. Presence of significant medical problems and any other neuropsychiatric disorder requiring drug therapy (e.g., Bipolar disorder, psychosis). 2. Weight less than 15 kg. 3. Other cardiac, liver, gastrointestinal, renal, endocrine, blood and metabolic diseases.

Design outcomes

Primary

Measure	Time frame
Clinical psychiatric improvement measured by CARS and ATEC before and after administration.	—

Countries

Africa

Contacts

Public ContactHosam Ahmad

Egypt Ministry of Health and population Internal Medicine and biomedical chemistry

hosam.refaei@yahoo.com+0201000638308

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026